10-14-2022

Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

06-27-2022

Bold Therapeutics BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference

05-10-2022

Bold Therapeutics to Present at Bio Korea 2022 as part of the Canadian Trade Delegation

04-06-2022

BOLD-100s Broad Potential Featured at the AACR Annual Meeting 2022

04-04-2022

Bold Therapeutics Selected as 2nd Place Winner at 2022 Innovator Pitch Challenge

03-10-2022

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers

01-13-2022

Bold Therapeutics and Hana Pharm Extend Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

09-16-2021

BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models

07-07-2021

Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers

06-23-2021

Bold Therapeutics Collaborates with Dr. Stephen Barr at Western University to Study BOLD-100 In COVID-19 Variants

06-09-2020

Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral

05-11-2021

FDA Grants Bold Therapeutics BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

04-16-2021

BOLD-100 Effective In Vitro Against COVID-19 Variants

04-09-2021

BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

01-08-2021

Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials

01-06-2021

Bold Therapeutics Collaborators at University of Vienna Published Study Detailing the Binding Partners and Mechanism of Action of BOLD-100

12-18-2020

Bold Therapeutics COVID-19 Program Chosen by National Research Council of Canada for Development Support

10-09-2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

08-17-2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

06-11-2020

Bold Therapeutics Expands COVID-19 Consortium

05-28-2020

Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

04-15-2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

03-27-2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

03-27-2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

02-10-2020

Bold Therapeutics Visiting Collaborators in Europe
View All